Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Orphan-drug pipelines create dense disclosures, and Travere Therapeutics’ filings are no exception. Pages of clinical trial data, sparsentan milestones, and liquidity notes often leave investors scanning for what matters. If you’ve ever wondered where to find “Travere Therapeutics insider trading Form 4 transactions” or how the company accounts for FDA fast-track expenses in a 10-Q, this page eliminates the guesswork. The result: Travere Therapeutics SEC filings explained simply.
Stock Titan’s AI reads every document the moment it hits EDGAR, then serves plain-English explanations. From the latest “Travere Therapeutics quarterly earnings report 10-Q filing” to a sudden “Travere Therapeutics 8-K material events explained,” our algorithms highlight cash runway, trial timelines, and risk factors. Real-time alerts keep you updated on “Travere Therapeutics Form 4 insider transactions real-time,” so you don’t miss an executive stock sale filed after the bell.
Need deeper context? Our platform links each form to the business questions professionals actually ask:
- “Travere Therapeutics annual report 10-K simplified” — see R&D spend, orphan-drug market size, and revenue projections in one view.
- “Travere Therapeutics proxy statement executive compensation” — compare CEO incentives to pivotal trial milestones.
- “Travere Therapeutics earnings report filing analysis” — track quarter-over-quarter pipeline progress without reading footnotes.
- “understanding Travere Therapeutics SEC documents with AI” — follow guided annotations inside each filing.
- “Travere Therapeutics executive stock transactions Form 4” — monitor patterns ahead of regulatory announcements.
Whether you’re modeling probability-of-approval or simply verifying cash reserves, Stock Titan delivers complete coverage, expert context, and AI-powered summaries that turn complex disclosures into actionable insights.
Christopher R. Cline, Chief Financial Officer of Travere Therapeutics, sold 470 shares of the company's common stock on 08/27/2025 at a price of $17.31 per share under a written plan intended to satisfy Rule 10b5-1(c). The filing reports 92,656 shares beneficially owned by Mr. Cline after the transaction.
The sale was executed pursuant to a 10b5-1 plan adopted on May 28, 2025 and included additional shares sold to cover the tax obligation arising from the vesting of performance-based restricted stock units that vested in May 2025. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 08/28/2025.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 8,876,000 shares of Travere Therapeutics (TVTX), representing 9.96% of the outstanding common stock. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and exercises shared voting and dispositive power over the shares. Mr. Steven Boyd, as managing member of Armistice Capital, is reported with the same shared voting and dispositive power. The filing states the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The percent ownership is calculated using 89,138,673 shares outstanding as of July 31, 2025, per the issuers SEC filing.
Selected financial highlights (three and six months ended June 30, 2025): Total revenue was $114.4 million for Q2 and $196.2 million for the six months. Net product sales were $94.8 million in Q2 (FILSPARI $71.9M, tiopronin $23.0M) vs. $52.2M a year ago. License and collaboration revenue included a $17.5 million regulatory milestone. Operating loss for the quarter was $12.7M; six-month net loss was $53.98M (basic/diluted loss per share YTD $0.61). Cash and cash equivalents were $75.2M and available-for-sale marketable debt securities were $244.4M (total liquid investments $319.5M). Total assets were $555.3M, total liabilities $522.6M, and stockholders' equity $32.7M.
Operational and programmatic items: FILSPARI previously received full U.S. approval (Sept 5, 2024) and the European conditional MA converted to a standard MA in April 2025, triggering the $17.5M milestone in May 2025. The company submitted an sNDA seeking FSGS approval; the FDA accepted the sNDA and set a PDUFA date of Jan 13, 2026 and plans an advisory committee. Pegtibatinase enrollment is on a voluntary pause due to manufacturing scale-up issues. Renalys licensing and other collaborations remain active.
FAQ
What is the current stock price of Travere Therapeutics (TVTX)?
What is the market cap of Travere Therapeutics (TVTX)?
